{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["Chinese herbal medicine", "drug-combination pharmacokinetic research", "multi-compound pharmacokinetic research", "pharmacokinetic compatibility", "pharmacokinetics"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "36114271", "DateCompleted": {"Year": "2022", "Month": "12", "Day": "02"}, "DateRevised": {"Year": "2022", "Month": "12", "Day": "02"}, "Article": {"ArticleDate": [{"Year": "2022", "Month": "09", "Day": "16"}], "Language": ["eng"], "ELocationID": ["10.1038/s41401-022-00983-7"], "Journal": {"ISSN": "1745-7254", "JournalIssue": {"Volume": "43", "Issue": "12", "PubDate": {"Year": "2022", "Month": "Dec"}}, "Title": "Acta pharmacologica Sinica", "ISOAbbreviation": "Acta Pharmacol Sin"}, "ArticleTitle": "Multi-compound and drug-combination pharmacokinetic research on Chinese herbal medicines.", "Pagination": {"StartPage": "3080", "EndPage": "3095", "MedlinePgn": "3080-3095"}, "Abstract": {"AbstractText": ["Traditional medicine has provided a basis for health care and disease treatment to Chinese people for millennia, and herbal medicines are regulated as drug products in China. Chinese herbal medicines have two features. They normally possess very complex chemical composition. This makes the identification of the constituents that are together responsible for the therapeutic action of an herbal medicine challenging, because how to select compounds from an herbal medicine for pharmacodynamic study has been a big hurdle in such identification efforts. To this end, a multi-compound pharmacokinetic approach was established to identify potentially important compounds (bioavailable at the action loci with significant exposure levels after dosing an herbal medicine) and to characterize their pharmacokinetics and disposition. Another feature of Chinese herbal medicines is their typical use as or in combination therapies. Coadministration of complex natural products and conventional synthetic drugs is prevalent worldwide, even though it remains very controversial. Natural product-drug interactions have raised wide concerns about reduced drug efficacy or safety. However, growing evidence shows that incorporating Chinese herbal medicines into synthetic drug-based therapies delivers benefits in the treatment of many multifactorial diseases. To address this issue, a drug-combination pharmacokinetic approach was established to assess drug-drug interaction potential of herbal medicines and degree of pharmacokinetic compatibility for multi-herb combination and herbal medicine-synthetic drug combination therapies. In this review we describe the methodology, techniques, requirements, and applications of multi-compound and drug-combination pharmacokinetic research on Chinese herbal medicines and to discuss further development for these two types of pharmacokinetic research."], "CopyrightInformation": "\u00a9 2022. The Author(s), under exclusive licence to Shanghai Institute of Materia Medica, Chinese Academy of Sciences and Chinese Pharmacological Society."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China. chli@simm.ac.cn."}], "LastName": "Li", "ForeName": "Chuan", "Initials": "C"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China."}], "LastName": "Jia", "ForeName": "Wei-Wei", "Initials": "WW"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China."}], "LastName": "Yang", "ForeName": "Jun-Ling", "Initials": "JL"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China."}], "LastName": "Cheng", "ForeName": "Chen", "Initials": "C"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China."}], "LastName": "Olaleye", "ForeName": "Olajide E", "Initials": "OE"}], "PublicationTypeList": ["Review", "Journal Article"]}, "MedlineJournalInfo": {"Country": "United States", "MedlineTA": "Acta Pharmacol Sin", "NlmUniqueID": "100956087", "ISSNLinking": "1671-4083"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Drugs, Chinese Herbal"}, {"RegistryNumber": "0", "NameOfSubstance": "Drug Combinations"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Drugs, Chinese Herbal"}, {"QualifierName": ["chemistry"], "DescriptorName": "Plants, Medicinal"}, {"QualifierName": [], "DescriptorName": "Medicine, Chinese Traditional"}, {"QualifierName": [], "DescriptorName": "Drug Combinations"}, {"QualifierName": [], "DescriptorName": "Drug Interactions"}], "CoiStatement": "The authors declare no competing interests."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Outline of the main points of prevention and treatment of epidemic diseases with traditional Chinese medicine. Beijing J Tradit Chin Med (Beijing Zhongyiyao). 2014;33:910\u20132."}, {"Citation": "Chinese National Health Commission and Chinese State Administration of Traditional Chinese Medicine, Diagnosis and Treatment of Adults with Coronavirus Disease 2019 (COVID-19) (the ninth version), March 15th, 2022 http://www.nhc.gov.cn/yzygj/s7653p/202203/b74ade1ba4494583805a3d2e40093d88/files/ef09aa4070244620b010951b088b8a27.pdf. (accessed on 27th March, 2022)"}, {"Citation": "Zhang BL. Traditional Chinese medicine in China\u2019s combating of Covid-19, brimming with cultural confidence. Red Flag Manuscr (Hongqi Wengao) 2021;6:37\u201340."}, {"Citation": "Ni LQ, Chen LL, Huang X, Han CP, Xu JR, Zhang H, et al. Combating COVID-19 with integrated traditional Chinese and Western medicine in China. Acta Pharm Sin B. 2020;10:1149\u201362.. doi: 10.1016/j.apsb.2020.06.009.", "ArticleIdList": ["10.1016/j.apsb.2020.06.009", "PMC7319939", "32834946"]}, {"Citation": "National Medical Products Administration, The notification regarding the implementation of Good Manufacturing Practice of Medical Products (version 2010), https://www.nmpa.gov.cn/xxgk/fgwj/gzwj/gzwjyp/20110225152101646.html. (Accessed 7 June 2022)."}, {"Citation": "Zhang BL, Chen CH, editors-in-chief. Modernization of Chinese medicine for twenty years (1996\u20132015). Shanghai: Shanghai Science & Technology Press; 2016."}, {"Citation": "National People\u2019s Congress Standing Committee. Drug Administration Law of the People\u2019s Republic of China. Beijing: Law Press China; 2019."}, {"Citation": "Wang C, Cao B, Liu QQ, Zou ZQ, Liang ZA, Gu L, et al. Oseltamivir compared with the Chinese traditional therapy Maxingshigan\u2013Yinqiaosan in the treatment of H1N1 influenza. Ann Intern Med. 2011;155:217\u201325. doi: 10.7326/0003-4819-155-4-201108160-00005.", "ArticleIdList": ["10.7326/0003-4819-155-4-201108160-00005", "21844547"]}, {"Citation": "Li XL, Zhang J, Huang J, Ma AQ, Yang JF, Li WM, et al. A multicenter, randomized, double-blind, parallel-group, placebo-controlled study of the effects of Qili Qiangxin capsules in patients with chronic heart failure. J Am Coll Cardiol. 2013;62:1065\u201372.. doi: 10.1016/j.jacc.2013.05.035.", "ArticleIdList": ["10.1016/j.jacc.2013.05.035", "23747768"]}, {"Citation": "Shang HC, Zhang JH, Yao C, Liu BY, Gao XM, Ren M, et al. Qi-Shen-Yi-Qi dripping pills for the secondary prevention of myocardial infarction: a randomised clinical trial. Evid Based Complement Altern Med. 2013;2013:738391. doi: 10.1155/2013/738391.", "ArticleIdList": ["10.1155/2013/738391", "PMC3725842", "23935677"]}, {"Citation": "Zhang L, Li P, Xing CY, Zhao JY, He YN, Wang JQ, et al. Efficacy and safety of Abelmoschus manihot for primary glomerular disease: a prospective, multicenter randomized controlled clinical trial. Am J Kidney Dis. 2014;64:57\u201365. doi: 10.1053/j.ajkd.2014.01.431.", "ArticleIdList": ["10.1053/j.ajkd.2014.01.431", "24631042"]}, {"Citation": "Song YL, Yao C, Yao YM, Han H, Zhao XD, Yu KJ, et al. XueBiJing injection versus placebo for critically ill patients with severe community-acquired pneumonia: a randomized controlled trial. Crit Care Med. 2019;47:e735\u201343. doi: 10.1097/CCM.0000000000003842.", "ArticleIdList": ["10.1097/CCM.0000000000003842", "PMC6727951", "31162191"]}, {"Citation": "Huang H, Ji LX, Song SY, Wang J, Wei N, Jiang M, et al. Identification of the major constituents in XueBiJing injection by HPLC-ESI-MS. Phytochem Anal. 2011;22:330\u20138. doi: 10.1002/pca.1284.", "ArticleIdList": ["10.1002/pca.1284", "21500296"]}, {"Citation": "Sun Z, Zuo LH, Sun TW, Tang JF, Ding DL, Zhou L, et al. Chemical profiling and quantification of XueBiJing injection, a systematic quality control strategy using UHPLC-Q exactive hybrid quadrupole-orbitrap high-resolution mass spectrometry. Sci Rep. 2017;7:16921. doi: 10.1038/s41598-017-17170-y.", "ArticleIdList": ["10.1038/s41598-017-17170-y", "PMC5717239", "29208914"]}, {"Citation": "Yu X, Niu W, Wang YY, Olaleye OE, Wang JN, Duan MY, et al. Novel assays for quality evaluation of XueBiJing: quality variability of a Chinese herbal injection for sepsis management. J Pharm Anal. 2022. 10.1016/j.jpha.2022.01.001.", "ArticleIdList": ["PMC9463487", "36105162"]}, {"Citation": "Yin Q, Li CS. Treatment effects of XueBiJing injection in severe septic patients with disseminated intravascular coagulation. Evid Based Complement Altern Med. 2014;2014:949254. doi: 10.1155/2014/949254.", "ArticleIdList": ["10.1155/2014/949254", "PMC3979062", "24778706"]}, {"Citation": "Wang Q, Wu X, Tong XW, Zhang ZL, Xu B, Zhou WG. XueBiJing ameliorates sepsis-induced lung injury by downregulating HMGB1 and RAGE expressions in mice. Evid Based Complement Altern Med. 2015;2015:860259.", "ArticleIdList": ["PMC4363585", "25821501"]}, {"Citation": "Wang L, Liu ZY, Dong Z, Pan JY, Ma XC. Effects of XueBiJing injection on microcirculation in septic shock. J Surg Res. 2016;202:147\u201354.. doi: 10.1016/j.jss.2015.12.041.", "ArticleIdList": ["10.1016/j.jss.2015.12.041", "27083961"]}, {"Citation": "Dong TH, Zhang GP, Dong K, Liu S, Yao YM. Research progress on mechanism of action of XueBiJing injection in the treatment of sepsis. Chin J Tradit Chin Med West Med Crit Care. 2016;23:554\u20137."}, {"Citation": "Chen X, Feng YX, Shen XY, Pan GX, Fan GW, Gao XM, et al. Anti-sepsis protection of XueBiJing injection is mediated by differential regulation of pro- and anti-inflammatory Th17 and T regulatory cells in a murine model of polymicrobial sepsis. J Ethnopharmacol. 2018;211:358\u201365.. doi: 10.1016/j.jep.2017.10.001.", "ArticleIdList": ["10.1016/j.jep.2017.10.001", "28987599"]}, {"Citation": "Cheng C, Lin JZ, Li L, Yang JL, Jia WW, Huang YH, et al. Pharmacokinetics and disposition of monoterpene glycosides derived from Paeonia lactiflora roots (Chishao) after intravenous dosing of antiseptic XueBiJing injection in human subjects and rats. Acta Pharm Sin. 2016;37:530\u201344. doi: 10.1038/aps.2015.103.", "ArticleIdList": ["10.1038/aps.2015.103", "PMC4820793", "26838074"]}, {"Citation": "Li XX, Cheng C, Wang FQ, Huang YH, Jia WW, Olaleye OE, et al. Pharmacokinetics of catechols in human subjects intravenously receiving XueBiJing injection, an emerging antiseptic herbal medicine. Drug Metab Pharmacokinet. 2016;31:95\u20138. doi: 10.1016/j.dmpk.2015.10.005.", "ArticleIdList": ["10.1016/j.dmpk.2015.10.005", "26830081"]}, {"Citation": "Zhang NT, Cheng C, Olaleye OE, Sun Y, Li L, Huang YH, et al. Pharmacokinetics-based identification of potential therapeutic phthalides from XueBiJing, a Chinese herbal injection used in sepsis management. Drug Metab Dispos. 2018;46::823\u201334. doi: 10.1124/dmd.117.079673.", "ArticleIdList": ["10.1124/dmd.117.079673", "29523601"]}, {"Citation": "Li J, Olaleye OE, Yu X, Jia WW, Yang JL, Lu C, et al. High degree of pharmacokinetic compatibility exists between the five-herb medicine XueBiJing and antibiotics comedicated in sepsis care. Acta Pharm Sin B. 2019;9:1035\u201349.. doi: 10.1016/j.apsb.2019.06.003.", "ArticleIdList": ["10.1016/j.apsb.2019.06.003", "PMC6804443", "31649852"]}, {"Citation": "Zheng R, Wang H, Liu Z, Wang XH, Li J, Lei X, et al. A real-world study on adverse drug reactions to XueBiJing injection: hospital intensive monitoring based on 93 hospitals (31,913 cases) Ann Transl Med. 2019;7:117. doi: 10.21037/atm.2018.09.26.", "ArticleIdList": ["10.21037/atm.2018.09.26", "PMC6465439", "31032272"]}, {"Citation": "Lu T, Yang JL, Gao XM, Chen P, Du FF, Sun Y, et al. Plasma and urinary tanshinol from Salvia miltiorrhiza (Danshen), can be used as pharmacokinetic markers for cardiotonic pills, a cardiovascular herbal medicine. Drug Metab Dispos. 2008;36:1578\u201386. doi: 10.1124/dmd.108.021592.", "ArticleIdList": ["10.1124/dmd.108.021592", "18474682"]}, {"Citation": "Liu HF, Yang JL, Du FF, Gao XM, Ma XT, Huang YH, et al. Absorption and disposition of ginsenosides after oral administration of Panax notoginseng extract to rats. Drug Metab Dispos. 2009;37:2290\u20138. doi: 10.1124/dmd.109.029819.", "ArticleIdList": ["10.1124/dmd.109.029819", "19786509"]}, {"Citation": "Li C. Multi-compound pharmacokinetic research on Chinese herbal medicines: approach and methodology. China J Chin Mater Med. 2017;42:607\u201317.", "ArticleIdList": ["28959826"]}, {"Citation": "Li C, Yang JL, Cheng C, Jia WW, Olaleye OE. Pharmacokinetic research on Chinese herbal medicines. Bull Jpn China Med Assoc. 2018;33:9\u201314."}, {"Citation": "Li C, Cheng C, Jia WW, Yang JL, Yu X, Olaleye OE. Multi-compound pharmacokinetic research on Chinese herbal medicines: identifying the medicines\u2019 potentially therapeutic compounds and characterizing their disposition and pharmacokinetics. Acta Pharm Sin. 2021;56:2426\u201346."}, {"Citation": "Fugh-Berman A. Herb-drug interactions. Lancet. 2000;355:134\u20138. doi: 10.1016/S0140-6736(99)06457-0.", "ArticleIdList": ["10.1016/S0140-6736(99)06457-0", "10675182"]}, {"Citation": "Hermann R, Richter O. Clinical evidence of herbal drugs as perpetrators of pharmacokinetic drug interactions. Planta Med. 2012;78:1458\u201377.. doi: 10.1055/s-0032-1315117.", "ArticleIdList": ["10.1055/s-0032-1315117", "22855269"]}, {"Citation": "Stieger B, Mahdi ZM, Jager W. Intestinal and hepatocellular transporters: therapeutic effects and drug interactions of herbal supplements. Annu Rev Pharm Toxicol. 2017;57:399\u2013416. doi: 10.1146/annurev-pharmtox-010716-105010.", "ArticleIdList": ["10.1146/annurev-pharmtox-010716-105010", "27648763"]}, {"Citation": "Zhang MM, Liu XM, Li J, He L, Tripathy D. Chinese medicinal herbs to treat the side-effects of chemotherapy in breast cancer patients. Cochrane Database Syst Rev. 2007;18:CD004921.", "ArticleIdList": ["PMC9028047", "17443560"]}, {"Citation": "Lam W, Bussom S, Guan FL, Jiang ZL, Zhang W, Gullen EA, Liu SH, Cheng YC. The four-herb Chinese medicine PHY906 reduces chemotherapy-induced gastrointestinal toxicity. Sci Transl Med. 2010;2:45ra59. doi: 10.1126/scitranslmed.3001270.", "ArticleIdList": ["10.1126/scitranslmed.3001270", "20720216"]}, {"Citation": "Jiang RR, Dong JJ, Li XX, Du FF, Jia WW, Xu F, et al. Molecular mechanisms governing different pharmacokinetics of ginsenosides and potential for ginsenoside-perpetrated herb-drug interactions on OATP1B3. Br J Pharmacol. 2015;172:1059\u201373. doi: 10.1111/bph.12971.", "ArticleIdList": ["10.1111/bph.12971", "PMC4314195", "25297453"]}, {"Citation": "Dong JJ, Olaleye OE, Jiang RR, Li J, Lu C, Du FF, et al. Glycyrrhizin has a high likelihood to be a victim of drug-drug interactions mediated by hepatic OATP1B1/1B3. Br J Pharmacol. 2018;175:3486\u2013503.. doi: 10.1111/bph.14393.", "ArticleIdList": ["10.1111/bph.14393", "PMC6086986", "29908072"]}, {"Citation": "Olaleye OE, Niu W, Du FF, Wang FQ, Xu F, Pintusophon S, et al. Inhibition of hepatic OATP1Bs by circulating saponins from intravenous ShenMai: potential joint precipitants of drug interactions. Acta Pharmacol Sin. 2019;40:833\u201349.. doi: 10.1038/s41401-018-0173-9.", "ArticleIdList": ["10.1038/s41401-018-0173-9", "PMC6786436", "30327544"]}, {"Citation": "Pintusophon S, Niu W, Duan XN, Olaleye OE, Huang YH, Wang FQ, et al. Intravenous formulation of Panax notoginseng root extract: human pharmacokinetics of ginsenosides and potential for perpetrating drug interactions. Acta Pharmacol Sin. 2019;40:1351\u201363.. doi: 10.1038/s41401-019-0273-1.", "ArticleIdList": ["10.1038/s41401-019-0273-1", "PMC6786404", "31358899"]}, {"Citation": "Li L, Zhao YS, Du FF, Yang JL, Xu F, Ren YH, et al. Intestinal absorption and presystemic elimination of various chemical constituents present in GBE50 extract, a standardized extract of Ginkgo biloba leaves. Curr Drug Metab. 2012;13:494\u2013509. doi: 10.2174/1389200211209050494.", "ArticleIdList": ["10.2174/1389200211209050494", "22292790"]}, {"Citation": "Chen F, Li L, Xu F, Sun Y, Du FF, Ma XT, et al. Systemic and cerebral exposure to and pharmacokinetics of flavonols and terpene lactones after dosing standardized Ginkgo biloba leaf extracts to rats via different administration routes. Br J Pharmacol. 2013;170:440\u201357. doi: 10.1111/bph.12285.", "ArticleIdList": ["10.1111/bph.12285", "PMC3834766", "23808355"]}, {"Citation": "Hu ZY, Yang JL, Cheng C, Huang YH, Du FF, Wang FQ, et al. Combinatorial metabolism notably affects human systemic exposure to ginsenosides from orally administered extract of Panax notoginseng roots (Sanqi) Drug Metab Dispos. 2013;41:1457\u201369. doi: 10.1124/dmd.113.051391.", "ArticleIdList": ["10.1124/dmd.113.051391", "23649704"]}, {"Citation": "Li MJ, Wang FQ, Huang YH, Du FF, Zhong CC, Olaleye OE, et al. Systemic exposure to and disposition of catechols, derived from Salvia miltiorrhiza roots (Danshen), after intravenous dosing DanHong injection in human subjects, rats, and dogs. Drug Metab Dispos. 2015;43:679\u201390. doi: 10.1124/dmd.114.061473.", "ArticleIdList": ["10.1124/dmd.114.061473", "25670806"]}, {"Citation": "Cheng C, Du FF, Yu K, Xu F, Wang FQ, Li L, et al. Pharmacokinetics and disposition of circulating iridoids and organic acids after intravenous administration of ReDuNing injection in rats. Drug Metab Dispos. 2016;44:1853\u20138. doi: 10.1124/dmd.116.071647.", "ArticleIdList": ["10.1124/dmd.116.071647", "27590023"]}, {"Citation": "Liu XW, Yang JL, Jia WW, Wen Q, Niu W, Duan XN, et al. Human pharmacokinetics of ginkgo terpene lactones and impact of carboxylation in blood on their platelet-activating factor antagonistic activity. Acta Pharmacol Sin. 2018;39:1935\u201346.. doi: 10.1038/s41401-018-0086-7.", "ArticleIdList": ["10.1038/s41401-018-0086-7", "PMC6289403", "30054600"]}, {"Citation": "Zhang HY, Niu W, Olaleye OE, Du FF, Wang FQ, Huang YH, et al. Comparison of intramuscular and intravenous pharmacokinetics of ginsenosides in humans after dosing XueShuanTong, a lyophilized extract of Panax notoginseng roots. J Ethnopharmacol. 2020;253:112658. doi: 10.1016/j.jep.2020.112658.", "ArticleIdList": ["10.1016/j.jep.2020.112658", "32035876"]}, {"Citation": "Lan XF, Olajide OE, Du FF, Yang JL, Shi YH, Yang W, et al. Pharmacokinetics-based identification of pseudoaldosterogenic compounds originating from Glycyrrhiza uralensis roots (Gancao) after dosing LianhuaQingwen capsule. Acta Pharmacol Sin. 2021;42:2155\u201372. doi: 10.1038/s41401-021-00651-2.", "ArticleIdList": ["10.1038/s41401-021-00651-2", "PMC8086230", "33931765"]}, {"Citation": "Koltermann A, Hartkorn A, Koch E, Furst R, Vollmar AM, Zahler S. Ginkgo biloba extract EGb761 increases endothelial nitric oxide production in vitro and in vivo. Cell Mol Life Sci. 2007;64:1715\u201322. doi: 10.1007/s00018-007-7085-z.", "ArticleIdList": ["10.1007/s00018-007-7085-z", "17497242"]}, {"Citation": "Wu YZ, Li SQ, Cui W, Zu XG, Wang FF, Du J. Ginkgo biloba extract improves coronary blood flow in patients with coronary artery disease: role of endothelial-dependent vasodilation. Planta Med. 2007;73:624\u20138. doi: 10.1055/s-2007-981536.", "ArticleIdList": ["10.1055/s-2007-981536", "17564952"]}, {"Citation": "Mashayekh A, Pham DL, Yousem DM, Dizon M, Barker PB, Lin DDM. Effects of Ginkgo biloba on cerebral blood flow assessed by quantitative MR perfusion imaging: a pilot study. Neuroradiology. 2011;53:185\u201391. doi: 10.1007/s00234-010-0790-6.", "ArticleIdList": ["10.1007/s00234-010-0790-6", "PMC3163160", "21061003"]}, {"Citation": "Ou HC, Lee WJ, Lee IT, Chiu TH, Tsai KL, Lin CY, et al. Ginkgo biloba extract attenuates oxLDL-induced oxidative functional damages in endothelial cells. J Appl Physiol. 2009;106:1674\u201385.. doi: 10.1152/japplphysiol.91415.2008.", "ArticleIdList": ["10.1152/japplphysiol.91415.2008", "19228986"]}, {"Citation": "Chen JW, Chen YH, Lin FY, Chen YL, Lin SJ. Ginkgo biloba extract inhibits tumor necrosis factor-induced reactive oxygen species generation, transcription factor activation, and cell adhesion molecule expression in human aortic endothelial cells. Arterioscler Thromb Vasc Biol. 2003;23:1559\u201366. doi: 10.1161/01.ATV.0000089012.73180.63.", "ArticleIdList": ["10.1161/01.ATV.0000089012.73180.63", "12893683"]}, {"Citation": "Chen JS, Huang PH, Wang CH, Lin FY, Tsai HY, Wu TC, et al. Nrf-2 mediated heme oxygenase-1 expression, an antioxidant-independent mechanism, contributes to anti-atherogenesis and vascular protective effects of Ginkgo biloba extract. Atherosclerosis. 2011;214:301\u20139. doi: 10.1016/j.atherosclerosis.2010.11.010.", "ArticleIdList": ["10.1016/j.atherosclerosis.2010.11.010", "21144518"]}, {"Citation": "Tsai JY, Su KH, Shyue SK, Kou YR, Yu YB, Hsiao SH, et al. EGb761 ameliorates the formation of foam cells by regulating the expression of SR-A and ABCA1: role of haem oxygenase-1. Cardiovasc Res. 2010;88:415\u201323. doi: 10.1093/cvr/cvq226.", "ArticleIdList": ["10.1093/cvr/cvq226", "20615914"]}, {"Citation": "Huang SY, Jeng C, Kao SC, Yu JJH, Liu DZ. Improved haemorrheological properties by Ginkgo biloba extract (Egb761) in type 2 diabetes mellitus complicated with retinopathy. Clin Nutr. 2004;23:615\u201321. doi: 10.1016/j.clnu.2003.10.010.", "ArticleIdList": ["10.1016/j.clnu.2003.10.010", "15297098"]}, {"Citation": "Luo Y, Smith JV, Paramasivam V, Burdick A, Curry KJ, Buford JP, et al. Inhibition of amyoid-\u03b2 aggregation and caspase-3 activation by the Ginkgo biloba extract EGb761. Proc Natl Acad Sci USA. 2002;99:12197\u2013202. doi: 10.1073/pnas.182425199.", "ArticleIdList": ["10.1073/pnas.182425199", "PMC129421", "12213959"]}, {"Citation": "Longpr\u00e9 F, Garneau P, Christen Y, Ramassamy C. Protection by Egb761 against \u03b2-amyloid-induced neurotoxicity: involvement of NF-\u03baB, SIRT1, and MAPKs pathways and inhibiton of amyloid fibril formation. Free Radic Biol Med. 2006;41:1781\u201394.. doi: 10.1016/j.freeradbiomed.2006.08.015.", "ArticleIdList": ["10.1016/j.freeradbiomed.2006.08.015", "17157181"]}, {"Citation": "Tchantchou F, Xu Y, Wu YJ, Christen Y, Luo Y. EGb761 enhances adult hippocampal neurogenesis and phosphorylation of CREB in transgenic mouse model of Alzheimer\u2019s disease. FASEB J. 2007;21:2400\u20138. doi: 10.1096/fj.06-7649com.", "ArticleIdList": ["10.1096/fj.06-7649com", "17356006"]}, {"Citation": "Saleem S, Zhuang H, Biswal S, Christen Y, Dor\u00e9 S. Ginkgo biloba extract neuroprotective action is dependent on heme oxygenase 1 in ischemic reperfusion brain injury. Stroke. 2008;39:3389\u201396. doi: 10.1161/STROKEAHA.108.523480.", "ArticleIdList": ["10.1161/STROKEAHA.108.523480", "PMC6010172", "18845796"]}, {"Citation": "Str\u00f8mgaard K, Nakanishi K. Chemistry and biology of terpene trilactones from Ginkgo biloba. Angew Chem Int Ed. 2004;43:1640\u201358. doi: 10.1002/anie.200300601.", "ArticleIdList": ["10.1002/anie.200300601", "15038029"]}, {"Citation": "Blumenthal M. The ABC Clinical Guide to Herbs. New York: Thieme; 2003. p. 185\u2013200."}, {"Citation": "van Beek TA, Montoro P. Chemical analysis and quality control of Ginkgo biloba leaves, extracts, and phytopharmaceuticals. J Chromatogr A. 2009;1216:2002\u201332.. doi: 10.1016/j.chroma.2009.01.013.", "ArticleIdList": ["10.1016/j.chroma.2009.01.013", "19195661"]}, {"Citation": "Lynch SV, Pedersen O. The human intestinal microbiome in health and disease. N Engl J Med. 2016;375:2369\u201379.. doi: 10.1056/NEJMra1600266.", "ArticleIdList": ["10.1056/NEJMra1600266", "27974040"]}, {"Citation": "Fan Y, Pedersen O. Gut microbiota in human metabolic health and disease. Nat Rev Microbiol. 2021;19:55\u201371. doi: 10.1038/s41579-020-0433-9.", "ArticleIdList": ["10.1038/s41579-020-0433-9", "32887946"]}, {"Citation": "Jia W, Li HK, Zhao LP, Nicholson JK. Gut microbiota: a potential new territory for drug targeting. Nat Rev Drug Discov. 2008;7:123\u20139. doi: 10.1038/nrd2505.", "ArticleIdList": ["10.1038/nrd2505", "18239669"]}, {"Citation": "He MQ, Shi BY. Gut microbiota as a potential target of metabolic syndrome: the role of probiotics and prebiotics. Cell Biosci. 2017;7:54. doi: 10.1186/s13578-017-0183-1.", "ArticleIdList": ["10.1186/s13578-017-0183-1", "PMC5655955", "29090088"]}, {"Citation": "Roberts AB, Gu XD, Buffa JA, Hurd AG, Wang ZN, Zhu WF, et al. Development of a gut microbe-targeted nonlethal therapeutic to inhibit thrombosis potential. Nat Med. 2018;24:1407\u201317. doi: 10.1038/s41591-018-0128-1.", "ArticleIdList": ["10.1038/s41591-018-0128-1", "PMC6129214", "30082863"]}, {"Citation": "Zeng X, Deng YH, Feng Y, Liu YM, Yang L, Huang Y, et al. Pharmacokinetics and safety of ginsenoside Rd following a single or multiple intravenous dose in healthy Chinese volunteers. J Clin Pharmacol. 2010;50:285\u201392. doi: 10.1177/0091270009344334.", "ArticleIdList": ["10.1177/0091270009344334", "19940231"]}, {"Citation": "Lu JL, Zeng XS, Zhou X, Yang JL, Ren LL, Long XY, et al. Molecular basis underlying hepatobiliary and renal excretion of phenolic acids of Salvia miltiorrhiza roots (Danshen) Front Pharmacol. 2022;13:911982. doi: 10.3389/fphar.2022.911982.", "ArticleIdList": ["10.3389/fphar.2022.911982", "PMC9127186", "35620286"]}, {"Citation": "Omar HR, Komarova I, El-Ghonemi M, Fathy A, Rashad R, Abdelmalak HD, et al. Licorice abuse: time to send a warning message. Ther Adv Endocrinol Metab. 2012;3:125\u201338. doi: 10.1177/2042018812454322.", "ArticleIdList": ["10.1177/2042018812454322", "PMC3498851", "23185686"]}, {"Citation": "Cinatl J, Morgenstern B, Bauer G, Chandra P, Rabenau H, Doerr HW. Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus. Lancet. 2003;361:2045\u20136. doi: 10.1016/S0140-6736(03)13615-X.", "ArticleIdList": ["10.1016/S0140-6736(03)13615-X", "PMC7112442", "12814717"]}, {"Citation": "Omar HR, Komarova I, El-Ghonemi M, Fathy A, Rashad R, Abdelmalak HD, et al. Licorice abuse: time to send a warning message. Ther Adv Endocrinol Metab. 2012;3:125\u201338. doi: 10.1177/2042018812454322.", "ArticleIdList": ["10.1177/2042018812454322", "PMC3498851", "23185686"]}, {"Citation": "Kato H, Kanaoka M, Yano S, Kobayashi M. 3-Monoglucuronyl-glycyrrhetinic acid is a major metabolite that causes licorice-induced pseudoaldosteronism. J Clin Endocrinol Metab. 1995;80:1929\u201333.", "ArticleIdList": ["7775643"]}, {"Citation": "Ohtake N, Kido A, Kubota K, Tsuchiya N, Morita T, Kase Y, et al. A possible involvement of 3-monoglucuronyl-glycyrrhetinic acid, a metabolite of glycyrrhizin (GL), in GL-induced pseudoaldosteronism. Life Sci. 2007;80:1545\u201352.. doi: 10.1016/j.lfs.2007.01.033.", "ArticleIdList": ["10.1016/j.lfs.2007.01.033", "17331546"]}, {"Citation": "Makino T, Ohtake N, Watanabe A, Tsuchiya N, Imamura S, Iizuka S, et al. Down-regulation of a hepatic transporter multidrug resistance-associated protein 2 is involved in alteration of pharmacokinetics of glycyrrhizin and its metabolites in a rat model of chronic liver injury. Drug Metab Dispos. 2008;36:1438\u201343. doi: 10.1124/dmd.108.021089.", "ArticleIdList": ["10.1124/dmd.108.021089", "18362159"]}, {"Citation": "Makino T, Okajima K, Uebayashi R, Ohtake N, Inoue K, Mizukami H. 3-Monoglucuronyl-glycyrrhretinic acid is a substrate of organic anion transporters expressed in tubular epithelial cells and plays important roles in licorice-induced pseudoaldosteronism by inhibiting 11\u03b2-hydroxysteroid dehydrogenase 2. J Pharmacol Exp Ther. 2012;342:297\u2013304. doi: 10.1124/jpet.111.190009.", "ArticleIdList": ["10.1124/jpet.111.190009", "22543032"]}, {"Citation": "Makino T. 3-Monoglucuronyl glycyrrhretinic acid is a possible marker compound related to licorice-induced pseudoaldosteronism. Biol Pharm Bull. 2014;37:898\u2013902. doi: 10.1248/bpb.b13-00997.", "ArticleIdList": ["10.1248/bpb.b13-00997", "24882402"]}, {"Citation": "Ishiuchi K, Morinaga O, Ohkita T, Tian CT, Hirasawa A, Mitamur M, et al. 18\u03b2-Glycyrrhetyl-3-O-sulfate would be a causative agent of licorice-induced pseudoaldosteronism. Sci Rep. 2019;9:1587. doi: 10.1038/s41598-018-38182-2.", "ArticleIdList": ["10.1038/s41598-018-38182-2", "PMC6367500", "30733510"]}, {"Citation": "Takahashi K, Yoshino T, Maki Y, Ishiuchi K, Namiki T, Ogawa-Ochiai K, et al. Identification of glycyrrhizin metabolites in humans and of a potential biomarker of liquorice-induced pseudoaldosteronism: a multi-centre cross-sectional study. Arch Toxicol. 2019;93:3111\u20139. doi: 10.1007/s00204-019-02588-2.", "ArticleIdList": ["10.1007/s00204-019-02588-2", "31605160"]}, {"Citation": "Morinaga O, Ishiuchi K, Ohkita T, Tian C-T, Hirasawa A, Mitamur M, et al. Isolation of a novel glycyrrhizin metabolite as a causal candidate compound for pseudoaldosteronism. Sci Rep. 2018;8:15568. doi: 10.1038/s41598-018-33834-9.", "ArticleIdList": ["10.1038/s41598-018-33834-9", "PMC6197257", "30348944"]}, {"Citation": "Chapman K, Holmes M, Seckl J. 11\u03b2-hydroxysteroid dehydrogenases: intracellular gate-keepers of tissue glucocorticoid action. Physiol Rev. 2013;93:1139\u2013206. doi: 10.1152/physrev.00020.2012.", "ArticleIdList": ["10.1152/physrev.00020.2012", "PMC3962546", "23899562"]}, {"Citation": "Hunter RW, Bailey MA. Glucocorticoids and 11\u03b2-hydroxysteroid dehydrogenases: mechanisms for hypertension. Curr Opin Pharmacol. 2015;21:105\u201314. doi: 10.1016/j.coph.2015.01.005.", "ArticleIdList": ["10.1016/j.coph.2015.01.005", "25666420"]}, {"Citation": "Jia Beditor-in-chief. FangjiXue (Chinese Medical Formulae: Therapeutic Effects and Use). Beijing, China Press of Traditional Chinese Medicine; 2016. Chinesey"}, {"Citation": "Morphy R, Kay C, Rankovic Z. From magic bullets to designed multiple ligands. Drug Discov Today. 2004;9:641\u201351. doi: 10.1016/S1359-6446(04)03163-0.", "ArticleIdList": ["10.1016/S1359-6446(04)03163-0", "15279847"]}, {"Citation": "Hopkins AL. Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol. 2008;4:682\u201390. doi: 10.1038/nchembio.118.", "ArticleIdList": ["10.1038/nchembio.118", "18936753"]}, {"Citation": "Mestres J, Gregori-Puigjan\u0107 E. Conciliating binding efficiency and polypharmacology. Trends Pharmacol Sci. 2009;30:470\u20134. doi: 10.1016/j.tips.2009.07.004.", "ArticleIdList": ["10.1016/j.tips.2009.07.004", "19717193"]}, {"Citation": "Peters J-U. Polypharmacology\u2014foe or friend? J Med Chem. 2013;56:8955\u201371. doi: 10.1021/jm400856t.", "ArticleIdList": ["10.1021/jm400856t", "23919353"]}, {"Citation": "Anighoro A, Bajorath J, Rastelli G. Polypharmacology: challenges and opportunities in drug discovery. J Med Chem. 2014;57:7874\u201387. doi: 10.1021/jm5006463.", "ArticleIdList": ["10.1021/jm5006463", "24946140"]}, {"Citation": "Korcsm\u00e1ros T, Szalay MS, B\u00f6de C, Kov\u00e1cs IA, Csermely P. How to design multi-target drugs. Expert Opin Drug Discov. 2007;2:799\u2013808. doi: 10.1517/17460441.2.6.799.", "ArticleIdList": ["10.1517/17460441.2.6.799", "23488998"]}, {"Citation": "Costantino L, Barlocco D. Designed multiple ligands: basic research vs clinical outcomes. Curr Med Chem. 2012;19:3353\u201387. doi: 10.2174/092986712801215883.", "ArticleIdList": ["10.2174/092986712801215883", "22680630"]}, {"Citation": "Proschak E, Stark H, Merk D. Polypharmacology by design: a medicinal chemist\u2019s perspective on multitargeting compounds. J Med Chem. 2019;62:420\u201344. doi: 10.1021/acs.jmedchem.8b00760.", "ArticleIdList": ["10.1021/acs.jmedchem.8b00760", "30035545"]}, {"Citation": "Leh\u00e1r J, Krueger AS, Avery W, Heilbut AM, Johansen LM, Price ER, et al. Synergistic drug combinations tend to improve therapeutically relevant selectivity. Nat Biotechnol. 2009;27:659\u201366. doi: 10.1038/nbt.1549.", "ArticleIdList": ["10.1038/nbt.1549", "PMC2708317", "19581876"]}, {"Citation": "Jia J, Zhu F, Ma XH, Cao ZW, Li YX, Chen YZ. Mechanisms of drug combinations: interaction and network perspective. Nat Rev Drug Discov. 2009;8:111\u201328. doi: 10.1038/nrd2683.", "ArticleIdList": ["10.1038/nrd2683", "19180105"]}, {"Citation": "Sun W, Sanderson PE, Zheng W. Drug combination therapy increases successful drug repositioning. Drug Discov Today. 2016;21:1189\u201395. doi: 10.1016/j.drudis.2016.05.015.", "ArticleIdList": ["10.1016/j.drudis.2016.05.015", "PMC4907866", "27240777"]}, {"Citation": "Shyr ZA, Cheng YS, Lo DC, Zheng W. Drug combination therapy for emerging viral diseases. Drug Discov Today. 2021;26:2367\u201376.. doi: 10.1016/j.drudis.2021.05.008.", "ArticleIdList": ["10.1016/j.drudis.2021.05.008", "PMC8139175", "34023496"]}, {"Citation": "Gradman AH, Basile JN, Carter BL, Bakris GL. Combination therapy in hypertension. J Am Soc Hypertens. 2010;4:90\u20138. doi: 10.1016/j.jash.2010.03.001.", "ArticleIdList": ["10.1016/j.jash.2010.03.001", "20400053"]}, {"Citation": "Al-Lazikani B, Banerji U, Workman P. Combinatorial drug therapy for cancer in the post-genomic era. Nat Biotechnol. 2012;30:679\u201392.. doi: 10.1038/nbt.2284.", "ArticleIdList": ["10.1038/nbt.2284", "22781697"]}, {"Citation": "Zhang MM, Liu XM, Li J, He L, Tripathy D. Chinese medicinal herbs to treat the side-effects of chemotherapy in breast cancer patients. Cochrane Database Syst Rev. 2007;18:CD004921.", "ArticleIdList": ["PMC9028047", "17443560"]}, {"Citation": "Lam W, Bussom S, Guan FL, Jiang ZL, Zhang W, Gullen EA, et al. The four-herb Chinese medicine PHY906 reduces chemotherapy-induced gastrointestinal toxicity. Sci Transl Med. 2010;2:45ra59. doi: 10.1126/scitranslmed.3001270.", "ArticleIdList": ["10.1126/scitranslmed.3001270", "20720216"]}, {"Citation": "Brantley SJ, Argikar AA, Lin YS, Nagar S, Paine MF. Herb-drug interactions: challenges and opportunities for improved predictions. Drug Metab Dispos. 2014;42:301\u201317. doi: 10.1124/dmd.113.055236.", "ArticleIdList": ["10.1124/dmd.113.055236", "PMC3935140", "24335390"]}, {"Citation": "Bailey DG, Spence JD, Munoz C, Arnold JMO. Interaction of citrus juices with felodipine and nifedipine. Lancet. 1991;37:268\u20139. doi: 10.1016/0140-6736(91)90872-M.", "ArticleIdList": ["10.1016/0140-6736(91)90872-M", "1671113"]}, {"Citation": "Bailey DG, Arnold JMO, Bend JR, Tran LT, Spence JD. Grapefruit juice-felodipine interaction: reproducibility and characterization with the extended release drug formulation. Br J Clin Pharmacol. 1995;40:135\u201340.", "ArticleIdList": ["PMC1365172", "8562295"]}, {"Citation": "Pirmohanmed M. Drug-grapefruit juice interactions: two mechanisms are clear but individual responses vary. BMJ. 2013;346:f1. doi: 10.1136/bmj.f1.", "ArticleIdList": ["10.1136/bmj.f1", "23297175"]}, {"Citation": "Ruschitzka F, Meier PJ, Turina M, Luscher TF, Noll G. Acute heart transplant rejection due to Saint John\u2019s wort. Lancet. 2000;355:548\u20139. doi: 10.1016/S0140-6736(99)05467-7.", "ArticleIdList": ["10.1016/S0140-6736(99)05467-7", "10683008"]}, {"Citation": "Breidenbach T, Kliem V, Burg M, Radermacher J, Hoffmann MW, Klempnauer J. Profound drop of cyclosporine a whole blood trough levels caused by St. John\u2019s wort (Hypericum perforatum) Transplantation. 2000;69:2229\u201330. doi: 10.1097/00007890-200005270-00052.", "ArticleIdList": ["10.1097/00007890-200005270-00052", "10852634"]}, {"Citation": "Barone GW, Gurley BJ, Ketel BL, Lightfoot ML, Abul-Ezz SR. Drug interaction between St. John\u2019s wort and cyclosporine. Ann Pharmacother. 2000;34:1013\u20136. doi: 10.1345/aph.10088.", "ArticleIdList": ["10.1345/aph.10088", "10981246"]}, {"Citation": "Sparreboom A, Cox MC, Acharya MR, Figg WD. Herbal remedies in the United States: potential adverse interactions with anticancer agents. J Clin Oncol. 2004;22:2489\u2013503. doi: 10.1200/JCO.2004.08.182.", "ArticleIdList": ["10.1200/JCO.2004.08.182", "15197212"]}, {"Citation": "Tachjian A, Maria V, Jahangir A. Use of herbal products and potential interactions in patients with cardiovascular diseases. J Am Coll Cardiol. 2010;55:515\u201325. doi: 10.1016/j.jacc.2009.07.074.", "ArticleIdList": ["10.1016/j.jacc.2009.07.074", "PMC2831618", "20152556"]}, {"Citation": "Yu K, Chen F, Li C. Absorption and disposition of saponins: what do we know and what do we need to know? Curr Drug Metab. 2012;13:577\u201398. doi: 10.2174/1389200211209050577.", "ArticleIdList": ["10.2174/1389200211209050577", "22292787"]}, {"Citation": "Ramanathan MR, Penzak SR. Pharmacokinetic drug interactions with Panax ginseng. Eur J Drug Metab Pharmacokinet. 2017;42:545\u201357. doi: 10.1007/s13318-016-0387-5.", "ArticleIdList": ["10.1007/s13318-016-0387-5", "27864798"]}, {"Citation": "Awortwe C, Makiwane M, Reuter H, Muller C, Louw J, Rosenkranz B. Critical evaluation of causality assessment of herb-drug interactions in patients. Br J Clin Pharmacol. 2018;84:679\u201393.. doi: 10.1111/bcp.13490.", "ArticleIdList": ["10.1111/bcp.13490", "PMC5867089", "29363155"]}, {"Citation": "Malati CY, Robertson SM, Hunt JD, Chairez C, Alfaro RM, Kovacs JA, et al. Influence of Panax ginseng on cytochrome P450 (CYP)3A and P-glycoprotein (P-gp) activity in healthy participants. J Clin Pharmacol. 2012;52:932\u20139. doi: 10.1177/0091270011407194.", "ArticleIdList": ["10.1177/0091270011407194", "PMC3523324", "21646440"]}, {"Citation": "Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Cui Y-Y, et al. Clinical assessment of effects of botanical supplementation on cytochrome P450 phenotypes in the elderly. Drug Aging. 2005;22:525\u201339. doi: 10.2165/00002512-200522060-00006.", "ArticleIdList": ["10.2165/00002512-200522060-00006", "PMC1858666", "15974642"]}, {"Citation": "Ismair MG, Stieger B, Cattori V, Hagenbuch B, Fried M, Meier PJ, et al. Hepatic uptake of cholecystokinin octapeptide by organic anion-transporting polypeptides OATP4 and OATP8 of rat and human liver. Gastroenterology. 2001;121:1185\u201390. doi: 10.1053/gast.2001.28704.", "ArticleIdList": ["10.1053/gast.2001.28704", "11677211"]}, {"Citation": "Ishiguro N, Maeda K, Kishimoto W, Saito A, Harada A, Ebner T, et al. Predominant contribution of OATP1B3 to the hepatic uptake of telmisartan, an angiotensin II receptor antagonist, in humans. Drug Metab Dispos. 2006;34:1109\u201315. doi: 10.1124/dmd.105.009175.", "ArticleIdList": ["10.1124/dmd.105.009175", "16611857"]}, {"Citation": "Letschert K, Faulstich H, Keller D, Keppler D. Molecular characterization and inhibition of amanitin uptake into human hepatocytes. Toxicol Sci. 2006;91:140\u20139. doi: 10.1093/toxsci/kfj141.", "ArticleIdList": ["10.1093/toxsci/kfj141", "16495352"]}, {"Citation": "Zhang AJ, Wang CY, Liu Q, Meng Q, Peng JY, Sun HJ, et al. Involvement of organic anion-transporting polypeptides in the hepatic uptake of dioscin in rats and humans. Drug Metab Dispos. 2013;41:994\u20131003. doi: 10.1124/dmd.112.049452.", "ArticleIdList": ["10.1124/dmd.112.049452", "23396419"]}, {"Citation": "Komoroski BJ, Zhang S-M, Cai H-B, Hutzler M, Frye R, Tracy TS, et al. Induction and inhibition of cytochromes P450 by the St. John\u2019s wort constituent hyperforin in human hepatocyte cultures. Drug Metab Dispos. 2004;32:512\u20138. doi: 10.1124/dmd.32.5.512.", "ArticleIdList": ["10.1124/dmd.32.5.512", "15100173"]}, {"Citation": "Asl MN, Hosseinzadeh H. Review of pharmacological effects of Glycyrrhiza sp. and its bioactive compounds. Phytother Res. 2008;22:709\u201324. doi: 10.1002/ptr.2362.", "ArticleIdList": ["10.1002/ptr.2362", "PMC7167813", "18446848"]}, {"Citation": "Li JY, Cao HY, Liu P, Cheng GH, Sun MY. Glycyrrhizic acid in the treatment of liver diseases: literature review. Biomed Res Int. 2014;2014:872139.", "ArticleIdList": ["PMC4052927", "24963489"]}, {"Citation": "Arase Y, Ikeda K, Murashima N, Chayama K, Tsubota A, Koida I, et al. The long term efficacy of glycyrrhizin in chronic hepatitis C patients. Cancer. 1997;79:1494\u2013500. doi: 10.1002/(SICI)1097-0142(19970415)79:8<1494::AID-CNCR8>3.0.CO;2-B.", "ArticleIdList": ["10.1002/(SICI)1097-0142(19970415)79:8<1494::AID-CNCR8>3.0.CO;2-B", "9118029"]}, {"Citation": "Expert Committee for Prevention and Management of Liver Inflammation, Chinese Society of Infectious Diseases. Consensus statement by the expert committee for prevention and management of liver inflammation in China. Chin J Hepatol. 2014;22:94\u2013103."}, {"Citation": "Expert Committee on Clinical Application of Glycyrrhizin Preparation in the Treatment of Liver Diseases. Expert consensus on clinical application of glycyrrhizin preparation in the treatment of liver diseases. J Clin Hepatol. 2016;32:844\u201352."}, {"Citation": "Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The third international consensus definitions for sepsis and septic shock (sepsis-3) J Am Med Assoc. 2016;315:801\u201310. doi: 10.1001/jama.2016.0287.", "ArticleIdList": ["10.1001/jama.2016.0287", "PMC4968574", "26903338"]}, {"Citation": "Cao Y, Chai YF, Deng Y, Fang BJ, Liu MH, Lu ZQ, et al. Chinese guidelines for emergency management of sepsis and septic shock 2018. J Clin Emerg. 2018;19:567\u201388."}, {"Citation": "Zhao GZ, Chen RB, Li B, Guo YH, Xie YM, Liao X, et al. Clinical practice guideline on traditional Chinese medicine therapy alone or combined with antibiotics for sepsis. Ann Transl Med. 2019;7:122. doi: 10.21037/atm.2018.12.23.", "ArticleIdList": ["10.21037/atm.2018.12.23", "PMC6465442", "31032277"]}, {"Citation": "Cao Y, Chai YF, Chen FY, Chen XH, Chen YG, Deng Y, et al. Chinese emergency medicine expert consensus on diagnosis and treatment of sepsis complicated with disseminated intravascular coagulation. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2017;29:577\u201380.", "ArticleIdList": ["28743331"]}, {"Citation": "Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med. 2017;43:304\u201377.. doi: 10.1007/s00134-017-4683-6.", "ArticleIdList": ["10.1007/s00134-017-4683-6", "28101605"]}, {"Citation": "Fink MP, Warren HS. Strategies to improve drug development for sepsis. Nat Rev Drug Discov. 2014;13:741\u201358. doi: 10.1038/nrd4368.", "ArticleIdList": ["10.1038/nrd4368", "25190187"]}, {"Citation": "Cohen J, Vincent JL, Adhikari NK, Machado FR, Angus DC, Calandra T, et al. Sepsis: a roadmap for future research. Lancet Infect Dis. 2015;15:581\u2013614. doi: 10.1016/S1473-3099(15)70112-X.", "ArticleIdList": ["10.1016/S1473-3099(15)70112-X", "25932591"]}, {"Citation": "Steinhagen F, Schmidt SV, Schewe JC, Peukert K, Klinman DM, Bode C. Immunotherapy in sepsis\u2014brake or accelerate? Pharmacol Ther. 2020;208:107476. doi: 10.1016/j.pharmthera.2020.107476.", "ArticleIdList": ["10.1016/j.pharmthera.2020.107476", "31931100"]}, {"Citation": "Li CY, Wang P, Zhang L, Li M, Lei X, Liu S, et al. Efficacy and safety of XueBiJing injection (a Chinese patent) for sepsis: a meta-analysis of randomized controlled trials. J Ethnopharmacol. 2018;224:512\u201321.. doi: 10.1016/j.jep.2018.05.043.", "ArticleIdList": ["10.1016/j.jep.2018.05.043", "29860133"]}, {"Citation": "Liu YC, Yao FH, Chai YF, Dong N, Sheng ZY, Yao YM. XueBiJing injection promotes M2 polarization of macrophages and improves survival rate in septic mice. Evid Based Complement Altern Med. 2015;2015:352642.", "ArticleIdList": ["PMC4441998", "26064161"]}, {"Citation": "Li AL, Li J, Bao YH, Yuan DS, Huang ZW. XueBiJing injection alleviates cytokine-induced inflammatory liver injury in CLP-induced septic rats through induction of suppressor of cytokine signaling 1. Exp Ther Med. 2016;12:1531\u20136. doi: 10.3892/etm.2016.3476.", "ArticleIdList": ["10.3892/etm.2016.3476", "PMC4998358", "27602076"]}, {"Citation": "Li TT, Qian YM, Miao ZL, Zheng PY, Shi T, Jiang XR, et al. XueBiJing injection alleviates Pam3CSK4-induced inflammatory response and protects mice from sepsis caused by methicillin-resistant staphylococcus aureus. Front Pharmacol. 2020;11:104. doi: 10.3389/fphar.2020.00104.", "ArticleIdList": ["10.3389/fphar.2020.00104", "PMC7047170", "32153410"]}, {"Citation": "Pea F, Furlanut M. Pharmacokinetic aspects of treating infections in the intensive care unit: focus on drug interactions. Clin Pharmacokinet. 2001;40:833\u201368. doi: 10.2165/00003088-200140110-00004.", "ArticleIdList": ["10.2165/00003088-200140110-00004", "11735605"]}, {"Citation": "Pereira JM, Paiva JA. Antimicrobial drug interactions in the critically ill patients. Curr Clin Pharmacol. 2013;8:25\u201338.", "ArticleIdList": ["22946870"]}, {"Citation": "Uijtendaal EV, van Harssel LL, Hugenholtz GW, Kuck EM. Zwart-van Rijkom JE, Cremer OL, et al. Analysis of potential drug-drug interactions in medical intensive care unit patients. Pharmacotherapy. 2014;34:213\u20139. doi: 10.1002/phar.1395.", "ArticleIdList": ["10.1002/phar.1395", "24390929"]}, {"Citation": "Danishuddin, Kumar V, Faheem M, Lee KW. A decade of machine learning-based predictive models for human pharmacokinetics: advances and challenges. Drug Discov Today. 2022;27:529\u201337. doi: 10.1016/j.drudis.2021.09.013.", "ArticleIdList": ["10.1016/j.drudis.2021.09.013", "34592448"]}, {"Citation": "Wright MR. Opportunities and considerations in the application of artificial intelligence to pharmacokinetic prediction. Methods Mol Biol. 2022;2390:461\u201382. doi: 10.1007/978-1-0716-1787-8_21.", "ArticleIdList": ["10.1007/978-1-0716-1787-8_21", "34731483"]}, {"Citation": "Clarke G, Sandhu KV, Griffin BT, Dinan TG, Cryan JF, Hyland NP. Gut reactions: breaking down xenobiotic-microbiome interactions. Pharmacol Rev. 2019;71:198\u2013224. doi: 10.1124/pr.118.015768.", "ArticleIdList": ["10.1124/pr.118.015768", "30890566"]}, {"Citation": "Hitchings R, Kelly L. Predicting and understanding the human microbiome\u2019s impact on pharmacology. Trends Pharmacol Sci. 2019;40:495\u2013505. doi: 10.1016/j.tips.2019.04.014.", "ArticleIdList": ["10.1016/j.tips.2019.04.014", "PMC6758919", "31171383"]}, {"Citation": "Wang YY, Chu ZX, Yang JL, Olaleye OE, He RR, Li MZ, et al. Poteial health benefits of resveratrol: a pharmacokinetics-caused conundrum. Chin J Clin Pharmacol Ther. 2021;26:931\u201354."}, {"Citation": "Hintze KJ, Cox JE, Rompato G, Benninghoff AD, Ward RE, Broadbent J, et al. Broad scope method for creating humanized animal models for animal health and disease research through antibiotic treatment and human fecal transfer. Gut Microbes. 2014;5:18391. doi: 10.4161/gmic.28403.", "ArticleIdList": ["10.4161/gmic.28403", "PMC4063843", "24637796"]}, {"Citation": "Arrieta M-C, Walter J, Finlay BB. Human microbiota-associated mice: a model with challenges. Cell Host Microbe. 2016;19:575\u20138. doi: 10.1016/j.chom.2016.04.014.", "ArticleIdList": ["10.1016/j.chom.2016.04.014", "27173924"]}, {"Citation": "Staley C, Kaiser T, Beura LK, Hamilton MJ, Weingarden AR, Bobr A, et al. Stable engraftment of human microbiota into mice with a single oral gavage following antibiotic conditioning. Microbiome. 2017;5:87. doi: 10.1186/s40168-017-0306-2.", "ArticleIdList": ["10.1186/s40168-017-0306-2", "PMC5537947", "28760163"]}, {"Citation": "Jia WW, Du FF, Liu XW, Jiang RR, Xu F, Yang JL, et al. Renal tubular secretion of tanshinol: molecular mechanisms, impact on its systemic exposure, and propensity for dose-related nephrotoxicity and for renal herb-drug interactions. Drug Metab Dispos. 2015;43:669\u201378. doi: 10.1124/dmd.114.062000.", "ArticleIdList": ["10.1124/dmd.114.062000", "25710938"]}, {"Citation": "Yamamura Y, Kawakami J, Santa T, Kotaki H, Uchino K, Sawada Y, et al. Pharmacokinetic profile of glycyrrhizin in healthy volunteers by a new high-performance liquid chromatographic method. J Pharm Sci. 1992;81:1042\u20136. doi: 10.1002/jps.2600811018.", "ArticleIdList": ["10.1002/jps.2600811018", "1432618"]}], "ReferenceList": []}], "History": [{"Year": "2022", "Month": "8", "Day": "5"}, {"Year": "2022", "Month": "8", "Day": "12"}, {"Year": "2022", "Month": "9", "Day": "17", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "12", "Day": "3", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "9", "Day": "16", "Hour": "23", "Minute": "25"}, {"Year": "2023", "Month": "12", "Day": "1"}], "PublicationStatus": "ppublish", "ArticleIdList": ["36114271", "PMC9483253", "10.1038/s41401-022-00983-7", "10.1038/s41401-022-00983-7"]}}], "PubmedBookArticle": []}